|Slideshows|July 24, 2019

8 Core Components of Psychotherapy

These simple tips may help take the mystery out of the process of psychotherapy and put us in a better position to understand our patients-and ourselves.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Psychotherapy and the Prevention of Relapse in Schizophrenia

ByMark L. Ruffalo, MSW, DPsa,Trisha M. Ruffalo, MSW

May 21st 2026

Advances in Ketamine-Assisted Psychotherapy

ByFernando Espí Forcén, MD, PhD

May 19th 2026

Podcast: The Intersection of Psychotherapy and Psychopharmacology for Mood Disorders. Optimizing Patient Outcomes With Holly A. Swartz, MD

ByJoseph F. Goldberg, MD,Holly A. Swartz, MD

May 1st 2026

Psychotherapies Can No Longer Afford to Compete With Each Other

ByAllen Frances, MD,Deven Dees

April 28th 2026

To Be or Not to Be…Congruent

ByDennis Palumbo, MA, MFT

April 17th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

8 Core Components of Psychotherapy

Related Content

Psychotherapy and the Prevention of Relapse in Schizophrenia

Advances in Ketamine-Assisted Psychotherapy

Podcast: The Intersection of Psychotherapy and Psychopharmacology for Mood Disorders. Optimizing Patient Outcomes With Holly A. Swartz, MD

Psychotherapies Can No Longer Afford to Compete With Each Other

To Be or Not to Be…Congruent

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression